Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
In Newfoundland and Labrador, the founder effect means there’s less genetic variability, making it easier to use population multi-omics to find true signals of disease — gene variants with low frequency but high impact. Sequence Bio works with leading pharma and biotech companies to discover better drug targets, build custom cohorts of volunteers for clinical trials, and shorten R&D timelines.
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules